FR2313939A1 - Polypeptides non immunogenes - Google Patents

Polypeptides non immunogenes

Info

Publication number
FR2313939A1
FR2313939A1 FR7425288A FR7425288A FR2313939A1 FR 2313939 A1 FR2313939 A1 FR 2313939A1 FR 7425288 A FR7425288 A FR 7425288A FR 7425288 A FR7425288 A FR 7425288A FR 2313939 A1 FR2313939 A1 FR 2313939A1
Authority
FR
France
Prior art keywords
biocatalyst
polyalkyl
immunogenic polypeptides
polyalkoxy
polyalkoxy polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7425288A
Other languages
English (en)
French (fr)
Other versions
FR2313939B1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp
Original Assignee
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp filed Critical Research Corp
Publication of FR2313939A1 publication Critical patent/FR2313939A1/fr
Application granted granted Critical
Publication of FR2313939B1 publication Critical patent/FR2313939B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR7425288A 1973-07-20 1974-07-19 Polypeptides non immunogenes Granted FR2313939A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38119173A 1973-07-20 1973-07-20

Publications (2)

Publication Number Publication Date
FR2313939A1 true FR2313939A1 (fr) 1977-01-07
FR2313939B1 FR2313939B1 (enExample) 1979-05-18

Family

ID=23504063

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7425288A Granted FR2313939A1 (fr) 1973-07-20 1974-07-19 Polypeptides non immunogenes

Country Status (9)

Country Link
JP (1) JPS5623587B2 (enExample)
CA (1) CA1033673A (enExample)
CH (1) CH616942A5 (enExample)
DE (1) DE2433883C2 (enExample)
FR (1) FR2313939A1 (enExample)
GB (1) GB1469472A (enExample)
IL (1) IL45291A0 (enExample)
NL (1) NL7409770A (enExample)
SE (1) SE441753B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0137361A3 (en) * 1983-09-23 1987-05-06 Hoechst Aktiengesellschaft Insulin derivatives modified in position b 30, process for their preparation, their vuse and pharmaceutical agents for the treatment of diabetes mellitus

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (de) * 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS59204130A (ja) * 1983-04-30 1984-11-19 Nippon Chemiphar Co Ltd 新規プラスミノ−ゲンアクチベ−タ誘導体を含有してなる経口投与薬剤
JPS61163687U (enExample) * 1985-03-28 1986-10-09
JPS62207485A (ja) * 1986-03-07 1987-09-11 大平技研工業株式会社 テレビゲ−ム機
US5037969A (en) * 1986-07-03 1991-08-06 Takeda Chemical Industries, Ltd. Glycosyl derivatives and use thereof
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU3423293A (en) * 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
US5578496A (en) * 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
DE60044827D1 (de) * 1999-09-10 2010-09-23 Procter & Gamble Polyoxyalkylen-konjugate als enzyminhibitoren
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
PT2939696E (pt) 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
EP1494706A4 (en) * 2002-03-26 2006-10-25 Biosynexus Inc ANTIMICROBIAL POLYMER CONJUGATES
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1553993B1 (en) * 2002-10-21 2016-03-30 Allvivo, Inc. Surface coating comprising bioactive compound
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7790835B2 (en) 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
AU2006257792A1 (en) * 2005-06-13 2006-12-21 Mdrna, Inc. Transmucosal delivery of peptide derivatives
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US10046058B2 (en) * 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US20170342211A1 (en) * 2016-05-31 2017-11-30 Robert Bosch Gmbh Azlactone functionalized substrates for conjugation of biomolecules
NZ788906A (en) * 2016-06-01 2025-07-25 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1585628A (enExample) * 1967-07-14 1970-01-30

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (enExample) * 1967-05-23 1971-08-02 Pharmacia Ab
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1585628A (enExample) * 1967-07-14 1970-01-30

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0137361A3 (en) * 1983-09-23 1987-05-06 Hoechst Aktiengesellschaft Insulin derivatives modified in position b 30, process for their preparation, their vuse and pharmaceutical agents for the treatment of diabetes mellitus

Also Published As

Publication number Publication date
FR2313939B1 (enExample) 1979-05-18
NL7409770A (nl) 1975-01-22
CH616942A5 (en) 1980-04-30
DE2433883C2 (de) 1986-03-27
IL45291A0 (en) 1974-10-22
SE441753B (sv) 1985-11-04
SE7409366L (enExample) 1975-01-21
GB1469472A (en) 1977-04-06
DE2433883A1 (de) 1976-02-05
JPS5042087A (enExample) 1975-04-16
CA1033673A (en) 1978-06-27
JPS5623587B2 (enExample) 1981-06-01

Similar Documents

Publication Publication Date Title
FR2313939A1 (fr) Polypeptides non immunogenes
DK341689A (da) Tvaerbindelige silylpolymerblandinger
BE846261A (fr) Procede de vulcanisation de compositions d'organosiloxane au moyen de microondes
ES411187A1 (es) Procedimiento para la preparacion de eteres heterociclicos.
ES449441A1 (es) Procedimiento para la fabricacion de nuevos derivados del alfa-fenilindol.
NO166451C (no) Fremgangsmaate for fremstilling av en loesning av en vannloeselig polymer.
ES441678A1 (es) Un procedimiento de obtencion de nuevas composiciones poli- meras.
ES428375A1 (es) Un procedimiento para preparar piperidinas disustituidas enlas posiciones 1 y 4.
BE771822A (fr) Hydroxy-2 phenoxy-4'benzophenones utilisables comme stabilisants de matieres organiques
ES440055A1 (es) Un procedimiento para la preparacion de acidos 19, 20-bis- norprotanoicos.
FR2281370A1 (fr) Complexes de l'o-chloranile et du 5,6,11,12-tetraselenotetracene, utilisables comme elements conducteurs organiques
ES427869A1 (es) Procedimiento para la preparacion de esteres alcoholicos deacido 5-fenilsulfinil-2-bencimidazol-carbamico.
SU480711A1 (ru) Способ получени производных 3-оксиметилтиазолиндиона-2,4
ES452391A1 (es) Procedimiento para la preparacion de nuevas arilalcohilami- nas sustituidas.
ES394637A1 (es) Procedimiento para estabilizar material organico posible dedegradacion oxidatica o termica.
ES392784A1 (es) Procedimiento para la preparacion de 3 beta - hidroxi - 5 alfa - cardenolidas y bufadienolidas.
JPS5566953A (en) Composition for continuously porous silicone rubber molded article
ES457416A1 (es) Un procedimiento para la preparacion de poli(tetrametilen- eter)glicol.
ES402328A1 (es) Procedimiento para preparar 4-hidroxibenzodio-xol.
ES407358A1 (es) Metodo para la preparacion de esteres y tiolesteres alifa- ticos.
ES428011A1 (es) Procedimiento para la preparacion de 2-amino-3,5-dibromo- bencilamina.
JPS5247899A (en) Process for preparing polymers of norbornene derivatives
ES403328A1 (es) Procedimiento para la preparacion de derivados de biciclo- alcano.
ES384868A1 (es) Un procedimiento de preparacion de derivados farmacodinami-camente activos de hidroxialcohilpiperazino.
ES415446A1 (es) Un procedimiento para la obtencion de derivados de acidos m-benzoilfenil alcanoicos.